Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Divestments (2017 - 2024)

Haemonetics has reported Divestments over the past 5 years, most recently at $1.5 million for Q1 2024.

  • Quarterly results put Divestments at $1.5 million for Q1 2024, changed N/A from a year ago — trailing twelve months through Mar 2024 was $1.5 million (down 85.9% YoY), and the annual figure for FY2025 was $43.3 million, up 2786.07%.
  • Divestments for Q1 2024 was $1.5 million at Haemonetics, down from $10.6 million in the prior quarter.
  • Over the last five years, Divestments for HAE hit a ceiling of $45.0 million in Q3 2020 and a floor of -$391000.0 in Q4 2020.
  • Median Divestments over the past 3 years was $6.1 million (2022), compared with a mean of $14.2 million.
  • Peak annual rise in Divestments hit 2821.74% in 2022, while the deepest fall reached 2821.74% in 2022.
  • Haemonetics' Divestments stood at -$391000.0 in 2020, then surged by 2821.74% to $10.6 million in 2022, then crashed by 85.9% to $1.5 million in 2024.
  • The last three reported values for Divestments were $1.5 million (Q1 2024), $10.6 million (Q1 2022), and -$391000.0 (Q4 2020) per Business Quant data.